Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness

Yoshitaka Fujii MD, Hidenori Toyooka MD,
Hiroyoshi Tanaka MD*

Purpose: This randomized, placebo-controlled, double-blind study was to evaluate the effects of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing postoperative nausea and vomiting in 110 patients with ($n = 50$) and without ($n = 60$) a history of motion sickness undergoing general anaesthesia for major gynaecological surgery.

Methods: The patients received a single dose of either granisetron ($40 \mu\text{g} \cdot \text{kg}^{-1}$) or placebo (saline) iv over 2–5 min immediately before induction of anaesthesia. Postoperatively, during the first 24 hr after anaesthesia, the frequencies of nausea and vomiting were recorded.

Results: Except for a positive history of motion sickness, the treatment groups were similar for patient characteristics, types of surgery, anaesthetics administered and opioids given. Postoperatively, the frequency of nausea was 44% and 16% after administration of placebo and granisetron in patients with motion sickness, and was 30% and 7% in patients without it, respectively; the corresponding frequencies of vomiting were 28%, 8%, 13% and 3%. The incidence of adverse events postoperatively were not different among the groups.

Conclusion: These results suggest that preoperative prophylactic administration of granisetron is effective and safe for

preventing postoperative nausea and vomiting in patients with motion sickness as well as in patients without it.

Objectif: Cette étude randomisée, contrôlée avec placebo et en double aveugle visait à évaluer les effets du granisetron, un antagoniste des récepteurs de type 3 de la 5-hydroxytryptamine, sur la prévention des nausées et des vomissements postopératoires chez 100 patientes avec ($n = 50$) ou sans ($n = 60$) antécédents de mal des transports subissant une anesthésie générale pour une chirurgie gynécologique majeure.

Méthodes: Les patientes ont reçu en une seule dose iv soit du granisetron ($40 \mu\text{g} \cdot \text{kg}^{-1}$), soit du soluté physiologique, en 2–5 min immédiatement avant l'induction de l'anesthésie. La fréquence des nausées et des vomissements a été enregistrée à la période postopératoire.

Résultats: À l'exception des antécédents de mal des transports, les caractéristiques des patientes, le type d'intervention, les anesthésiques et les morphiniques administrés étaient identiques. En postopératoire, la fréquence des nausées a été de 44% et de 16% respectivement pour le placebo et le granisetron chez les patientes souffrant de mal des transports et de 30% et de 7% chez celles qui n'en souffraient pas; les fréquences correspondantes pour les vomissements ont été de 28%, 8%, 13% et de 3%. L'incidence des complications postopératoires n'a pas différé entre les groupes.

Conclusion: Ces résultats suggèrent que l'administration prophylactique préopératoire de granisetron peut prévenir efficacement et en toute sécurité les nausées et les vomissements postopératoires chez les patientes qui souffrent du mal des transports comme chez celles qui n'en souffrent pas.

Key words:

COMPLICATIONS: nausea, vomiting;

SURGERY: gynaecological;

VOMITING: antiemetics, granisetron, incidence, motion sickness, nausea, postoperative.

From the Department of Anaesthesiology and Critical Care Medicine, Tokyo Medical and Dental University School of Medicine, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113, Japan and the *Department of Anaesthesiology, Toride Kyodo General Hospital, 2-1-1, Hongo, Toride City, Ibaraki 302, Japan

Phone: 03-3813-6111 (5325). Fax: 03-5803-0150

Address correspondence to: Dr. Y. Fujii.

Accepted for publication 6th October, 1995.

Postoperative nausea and vomiting occur frequently in patients undergoing general anaesthesia for major gynaecological surgery.¹ A number of factors which include age, obesity, history of motion sickness, operative procedure, anaesthetic techniques and postoperative pain are considered to increase the incidence of these

symptoms postoperatively.² A positive history of motion sickness is an important factor that increases the probability that a patient will experience postoperative emesis.³ Granisetron (Kytril®) is a selective 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonist, and is effective in preventing emesis associated with chemotherapy in patients with cancer.⁴ Recently, we have demonstrated that granisetron reduces the frequency of postoperative nausea and vomiting.^{5,6} However, the antiemetic effects of this agent on the frequency of postoperative emesis in patients with a history of motion sickness have not been reported. This study was designed to assess the efficacy of granisetron in a randomized, double-blind comparison with placebo in patients with and without motion sickness undergoing general anaesthesia for major gynaecological surgery.

Methods

After approval of our institutional review board, 50 female patients with a history of motion sickness and 60 women patients without it undergoing general anaesthesia for major gynaecological surgery were studied. A history of motion sickness was collected as a part of the demographic information. Thus, the patient was regarded to have motion sickness when she gave a recent history of any of the four symptoms on preoperative questionnaire, i.e., nausea, vomiting, loss of appetite and stomach awareness provoked by the transport with car, train or airplane. Informed consent was obtained from each patient. The patients ranged in age from 21 to 63 yr and were ASA physical status I or II. No patient had cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological disease nor had received any antiemetic within 24 hr of surgery. A negative pregnancy test result was obtained for each patient.

As premedication, all patients received atropine sulphate 0.5 mg *im* 30 min before induction of anaesthesia. In the operating room, the patients were placed in the lateral decubitus position. A 17-gauge Touhy needle was inserted at either L₂₋₃ or L₃₋₄ interspace with the loss of resistance technique, and an 18-gauge epidural catheter was placed cephalad (approximately 5 cm) through the needle. Correct placement of the catheter was confirmed by administering a test dose of 2 ml lidocaine (plain) 1.5%. After catheter placement, the patients were placed in the supine position. The patients of either group received, in a randomized, double-blind manner, a single dose of either granisetron (40 µg · kg⁻¹) or placebo (saline) *iv* over 2–5 min immediately before induction of anaesthesia. Anaesthesia was induced with thiopentone 5 mg · kg⁻¹ *iv* and vecuronium 0.2 mg · kg⁻¹ *iv* was used to facilitate tracheal intubation. After tracheal intubation, anaesthesia was maintained with

nitrous oxide 4 L · min⁻¹, oxygen 2 L · min⁻¹ and isoflurane 0.5–2.0% (inspired concentration). Ventilation was controlled mechanically and was adjusted to keep PETCO₂ between 35 and 40 mmHg with an anaesthetic/respiratory gas analyzer (Capnomac Ultima, Datex, Finland). When haemodynamic variables were stable, 10–15 ml lidocaine (plain) 1.5% were injected through the epidural catheter. Neuromuscular blocking drugs were used as needed. Isoflurane inhalation was terminated approximately ten minutes before the end of surgery. At the cessation of surgery, nitrous oxide administration was stopped, and atropine sulphate 0.02 mg · kg⁻¹ *iv* and neostigmine 0.04 mg · kg⁻¹ *iv* were administered for reversal of muscle relaxation, and then the tracheas were extubated. Rectal temperature was monitored and maintained at 37 ± 1°C. If two or more episodes of vomiting occurred during the 24 hr after anaesthesia, rescue antiemetics (e.g., metoclopramide) were given. For postoperative analgesia, a continuous epidural infusion with a mixture of 40 ml bupivacaine 0.25% and morphine 0.1 mg · kg⁻¹ was started after the completion of surgery at a rate of 1.7 ml · hr⁻¹ (Drug infusion balloon catheter, Dib international, Japan). Postoperatively, patients in all groups received indomethacin (50 mg, *pr*) when they complained of pain.

Postoperatively, at 24 hr after recovery from anaesthesia, episodes of nausea and vomiting experienced by the patients during the first 24 hr after anaesthesia were recorded by questioning directly by anaesthetists who were blinded to which antiemetics the patients had received. Retching was not assessed as a separate entity, and patients who experienced retching were classified as nauseous.⁷ The details of any side effect were also recorded throughout the study (0–24 hr after anaesthesia) following either general questioning of the patients by anaesthetists or spontaneous comment by the patients. Drowsiness/sedative was graded on a two-point scale and was assessed as 0 = awake, 1 = drowsy/sedative.⁸

Patient demographic data were analyzed with one-way analysis of variance (ANOVA) and Student's *t* test. The frequency of postoperative emesis and the incidence of adverse events were compared with a nonparametric test (χ^2). A *P* value of <0.05 was considered significant. All values were expressed as mean ± SD.

Results

Except for a history of motion sickness, patient characteristics and types of operation were not different among the groups (Table I).

During the first 24 hr after anaesthesia, the frequencies of postoperative nausea and vomiting in patients

TABLE I Patient characteristics and surgical procedures

Group	Motion sickness (+)		Motion sickness (-)	
	Placebo (n = 25)	Granisetron (n = 25)	Placebo (n = 30)	Granisetron (n = 30)
Age (yr)	44.2 ± 9.3	42.6 ± 7.3	41.7 ± 8.0	44.6 ± 8.1
Height (cm)	154.2 ± 5.3	152.8 ± 4.6	155.0 ± 5.7	155.3 ± 5.7
Weight (kg)	54.7 ± 6.8	53.1 ± 8.0	53.6 ± 6.6	55.6 ± 8.5
Duration of operation (min)	68.3 ± 26.5	76.4 ± 26.9	78.4 ± 29.3	78.1 ± 29.6
Duration of anaesthesia (min)	94.5 ± 24.7	97.8 ± 26.0	100.9 ± 30.5	102.6 ± 29.6
Morphine administered (epidural) after operation (mg)	5.4 ± 0.8	5.2 ± 0.8	5.3 ± 0.7	5.5 ± 0.7
Types of operation performed				
- Abdominal hysterectomy	20	19	22	23
- Vaginal hysterectomy	0	1	1	0
- Salpingo-oophorectomy	3	4	5	5
- Others	2	1	2	2

All values are expressed as mean ± SD.

TABLE II Number (percentage) of patients experienced nausea and vomiting during 0–24 hr after anaesthesia

Group	Motion sickness (+)			Motion sickness (-)		
	Placebo (n = 25)	Granisetron (n = 25)	P values	Placebo (n = 30)	Granisetron (n = 30)	P values
No.(%) of patients experienced nausea	11 (44%)	4 (16%)	<i>P</i> = 0.031	9 (30%)	2 (7%)	<i>P</i> = 0.019
No.(%) of patients experienced vomiting	7 (28%)	2 (8%)	<i>P</i> = 0.066	4 (13%)	1 (3%)	<i>P</i> = 0.161
Total no.(%) of patients experienced nausea and vomiting	18 (72%)	6 (24%)	<i>P</i> = 0.001	13 (43%)	3 (10%)	<i>P</i> = 0.004

with motion sickness who had received granisetron (24%) were lower than those who had received placebo (72%) (*P* < 0.05). Similarly, the frequencies of postoperative emesis in patients without motion sickness who had received granisetron (10%) were lower than those who had received placebo (43%) (*P* < 0.05) (Table II).

The frequencies of postoperative nausea and vomiting during the 24 hr after anaesthesia in patients with motion sickness who had received placebo were different from those in patients without it (*P* < 0.05) (Table III).

No additional antiemetics were administered in either group. The frequency of the use of indomethacin was 4–8% in each group. The most frequently reported adverse events were headache, dizziness and drowsiness (Table III). There were no differences in the incidence of these events among groups.

Discussion

The major findings of this study were that during the 24

hr after anaesthesia, the frequencies of postoperative nausea and vomiting in patients with a history of motion sickness were higher than those in patients without such a history when they received placebo (*P* < 0.05), and that frequencies of postoperative emesis in patients with and without motion sickness who had received granisetron was lower than in those who had received placebo (*P* < 0.05).

The aetiology of nausea and vomiting in patients undergoing general anaesthesia for major gynaecological surgery is multifactorial in origin.² A number of factors including age, obesity, history of motion sickness, surgical procedure, types of anaesthesia and postoperative pain are considered to increase the incidence of these postoperative symptoms. In this study, however, the treatment groups were similar for patient characteristics, surgical procedures, anaesthetics administered and analgesics used postoperatively, except for a history of motion sickness. Therefore, the differences in the frequencies of postoperative emesis between the patients

TABLE III Adverse events

Group	Motion sickness (+)		Motion sickness (-)	
	Placebo (n = 25)	Granisetron (n = 25)	Placebo (n = 30)	Granisetron (n = 30)
Headache	2	2	2	2
Dizziness	2	1	2	1
Drowsiness	1	1	1	1
Others	1	1	1	1
Total number adverse events	6	5	6	5

who had received placebo and those who had received granisetron can be attributed to the differences in these agents tested.

Postoperative nausea and vomiting are said to occur more commonly in patients with a positive history of motion sickness.³ This study also showed that frequencies of postoperative emesis during the 24 hr after anaesthesia in patients with motion sickness who had received placebo were higher than those without it.

In our trial of 110 patients with and without motion sickness, the frequencies of postoperative nausea and vomiting were less after administration of prophylactic granisetron than after placebo. This higher antiemetic efficacy of granisetron may possibly be explained by its pharmacological properties. Granisetron is effective in the treatment of nausea and vomiting induced by cancer therapy.⁴ Our recent studies have also demonstrated that granisetron has a potent antiemetic effect on nausea and vomiting following major gynaecological surgery.^{5,6} The exact mechanism of action of granisetron in preventing postoperative emesis remains unclear, but it has been suggested that it may act on sites containing 5-HT₃ receptors with demonstrated antiemetic effects.⁹

The effective doses of granisetron are known to be between 40 and 80 $\mu\text{g} \cdot \text{kg}^{-1}$ for the treatment of cancer therapy-induced nausea and vomiting.¹⁰ As previously shown, granisetron 40 $\mu\text{g} \cdot \text{kg}^{-1}$ was the optimal antiemetic effective dose for preventing postoperative emesis.⁶ Therefore, this dose was used in this study.

Motion sickness susceptibility predisposes to postoperative nausea and vomiting,³ but few studies have addressed the issue. In this study, the frequencies of postoperative nausea and vomiting were reduced with granisetron in patients without motion sickness, and this agent also appeared to be effective in control the postoperative emesis in patients with motion sickness. This study also suggests that patients with a positive history of motion sickness warrant consideration of prophylactic administration of antiemetic agent.

Adverse events observed in this study were relatively mild, and there were no differences in the incidence of

side effects among the groups. It does not appear that granisetron affects mental status to produce headache, dizziness or drowsiness. Thus, granisetron is relatively free of adverse events and is safe for preventing postoperative nausea and vomiting.

Our hospital pharmacy pays 10,020¥ for granisetron 3 mg, and this agent is much more expensive than other antiemetics (e.g., 175¥ for droperidol 2.5 mg, 61¥ for metoclopramide 10 mg). However, unlike granisetron, these antiemetics have undesirable side effects including excessive sedation, hypotension and extrapyramidal symptoms.^{1,11}

In conclusion, this study suggests that granisetron reduces the incidence of postoperative emesis both in patients with and without motion sickness.

References

- 1 McKenzie R, Wadhwa RK, Uy NTL, *et al.* Antiemetic effectiveness of intramuscular hydroxyzine compared with intramuscular droperidol. *Anesth Analg* 1981; 60: 783–8.
- 2 Watcha MF, White RF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. *Anesthesiology* 1992; 77: 162–84.
- 3 Kamath B, Curran J, Hawkey C, *et al.* Anaesthesia, movement and emesis. *Br J Anaesth* 1990; 64: 728–30.
- 4 Bermudez J, Boyle EA, Miner WD, Sanger GJ. The anti-emetic potential of the 5-hydroxytryptamine₃ receptor antagonist BRL 43694. *Br J Cancer* 1988; 58: 644–50.
- 5 Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. *Can J Anaesth* 1994; 41: 291–4.
- 6 Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. *Can J Anaesth* 1994; 41: 794–7.
- 7 Leeser J, Lip H. Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT₃ receptor antagonist. *Anesth Analg* 1991; 72: 751–5.
- 8 Fujii Y, Tanaka H, Toyooka H. Prevention of postoperative nausea and vomiting with granisetron: a randomized, double-blind comparison with droperidol. *Can J Anaesth* 1995; 42: 852–6.

- 9 Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT₃ receptor antagonist: correlation with anti-emetic response. *Cancer Chemother Pharmacol* 1989; 24: 45–9.
- 10 Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs, (I). Optimal dose-finding study. (Japanese) *Journal of Clinical and Therapeutic Medicine* 1990; 6: 49–61.
- 11 Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. *Anesth Analg* 1979; 58: 396–400.

RETRACTED ARTICLE